EZH2 and breast carcinoma: Moreover, Li et al. demonstrated that AMPK can phosphorylate EZH2 at T311 residue, again inhibiting the EZH2 binding to SUZ12 and resulting in an attenuation of the PRC2-dependent methylation of H3K27 in cancers such as ovarian and breast cancers [66].